source
- AstraZeneca’s oral relaxin drug shows partial success in mid-stage heart-failure trialAstraZeneca reported that its oral relaxin agonist improved cardiac function in a subset of patients enrolled in a mid-stage heart‑failure study. The trial demonstrated measurable benefits for some…
- Arrowhead's RNAi drug Redemplo shows safety advantage over Ionis in late-stage triglyceride trialsAt the European Society of Cardiology meeting in Munich, Arrowhead Pharmaceuticals presented new data on its RNA interference candidate Redemplo. Redemplo was evaluated in two late-stage studies i…